TP53 and cancer: Hinokiflavone also exhibited lower IC50 values in AML-2 and HCT116 p53 wild-type cells compared to HL-60 and HCT116 p53 null cells, suggesting that the cancer cells that have wild-type p53 were more sensitive to Hinokiflavone treatment.